Circulating Micro RNAs Expression in Egyptian Bronchial Asthma and COPD Patients

NCT02719145 | Completed DMC

• 1 other identifier: TFMEC1015
• Study Type: observational
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

This cross sectional study will be carried out on 30 subjects who will be recruited from the outpatient clinic of Chest Department, Tanta University Hospital. They will be classified into 3 groups: Group I: It will include 10 healthy volunteer subjects. Group II: It will include 10 asthmatic patients. Group III: It will include 10 COPD patients. miR-7, miR-20a, miR-21, miR-22, miR-145 and miR-155 will be measured in serum samples from all subjects

Conditions

Asthma; COPD

Keywords

micro RNA; asthma; COPD

Outcome Measures

Primary Outcomes (1)

• miR-7, miR-20a, miR-21, miR-22, miR-145 and miR-155 in serum samples from control, asthma and COPD Egyptian subjects.

  6 months.

Study Arms (3)

Control group (group 1)

10 healthy volunteer subjects.

Asthma group (group 2)

10 asthmatic patients.

COPD group (group 3)

10 COPD patients.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This cross sectional study will be carried out on 30 subjects who will be recruited from the outpatient clinic of Chest Department, Tanta University Hospital. They will be classified into 3 groups: Group I: It will includ 10 healthy volunteer subjects. Group II: It will include 10 asthmatic patients. Group III: It will include 10 COPD patients.

You may qualify if:

• Group 1: healthy volunteers with no history of chest troubles.
• Group 2: 10 asthmatic patients with history of paroxysmal wheezing, dyspnea, chest distress, and/or coughing; with Reversible airflow limitation as will be measured by an increase in forced expiratory volume in one second (FEV1) of at least 12% and of more than 200 ml after inhalation of 200 μg salbutamol.
• Group 3: 10 COPD patients who have chronic airflow limitation on spirometry (FEV1/FVC is less than 0.7), and the patients have irreversible airflow limitation as will be measured by an increase in (FEV1) by less than12% or less than 200 ml after inhalation of 200 μg salbutamol.

You may not qualify if:

• Upper or lower respiratory tract infection during the month preceding the study.
• Other chronic respiratory or systemic illness.
• Usage of systemic steroids within 2 months prior to the study.
• Inability to provide informed consent or who refused to draw off blood.

Sponsors & Collaborators

• Tanta University: lead

Study Sites (1)

Chest Department, Faculty of Medicine, Tanta University

Tanta, Gharbia Governorate, 31111, Egypt

Location

Related Publications (2)

• Van Pottelberge GR, Mestdagh P, Bracke KR, Thas O, van Durme YM, Joos GF, Vandesompele J, Brusselle GG. MicroRNA expression in induced sputum of smokers and patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011 Apr 1;183(7):898-906. doi: 10.1164/rccm.201002-0304OC. Epub 2010 Oct 29.

  PMID: 21037022 RESULT

• Wang Y, Yang L, Li P, Huang H, Liu T, He H, Lin Z, Jiang Y, Ren N, Wu B, Kamp DW, Tan J, Liu G. Circulating microRNA Signatures Associated with Childhood Asthma. Clin Lab. 2015;61(5-6):467-74. doi: 10.7754/clin.lab.2014.141020.

  PMID: 26118177 RESULT

Biospecimen

Retention: SAMPLES WITH DNA

Serum

MeSH Terms

Conditions

Asthma; Pulmonary Disease, Chronic Obstructive

Condition Hierarchy (Ancestors)

Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Adel S Bediwy, MD

  Chest Department, Faculty of Medicine, Tanta University

  STUDY CHAIR

• Salwa A Ganna, MD

  Chest Department, Faculty of Medicine, Tanta University

  PRINCIPAL INVESTIGATOR

• Said Hammad, MD

  Clinical Pathology Department, Faculty of Medicine, Tanta University

  PRINCIPAL INVESTIGATOR

• Abdel-Aziz A Zidan, PHD

  Director of Genomics and Proteomics Unit, Center of Excellence in Cancer Research, Tanta University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: March 19, 2016
• First Posted: March 25, 2016
• Study Start: October 1, 2015
• Primary Completion: June 1, 2016
• Study Completion: September 1, 2016
• Last Updated: April 25, 2018

Record last verified: 2018-04

Locations

EG (1)